Furthermore, to enhance the ability of CTCs to predict CRC recurrence, not only the application of CTC subtypes (e.g., EMT-related CTCs, CCSCs, and CTC clusters) but also the combination of CTC-related parameters with clinicopathological factors (e.g., tumor severity, lymph node metastasis, and vascular invasion) and laboratory markers (e.g., CEA, CA72-4, and CA-199) to establish a multimarker model for CRC recurrence are feasible strategies that will improve the detection rate and prediction performance for CRC recurrence. The gene discussed is CEACAM5; the disease is neoplasm.